Author:
Martinez-Martin F.,Corbella E.,Sarasa I.,Trias F.,Petitbò D.,Licerán M.,Sánchez-Hernández R.M.,Martin D.,Sánchez A.,Arnás C.,de Dios S.,Florido M.,Pintó X.
Subject
Family Practice,Public Health, Environmental and Occupational Health
Reference30 articles.
1. Low-density lipoproteins cause atherosclerotic cardiovascular disease 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;Eur Heart J,2017
2. ESC Scientific Document Group 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk;Mach;Eur Heart J Atherosc,2019
3. Da Vinci study EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the Da Vinci study;Ray;Eur J Prev Cardiol,2020
4. Manejo del paciente con dislipidemia en España. Proyecto Cardio Right Care Control del Riesgo Cardiovascular;Barrios;Semergen,2021
5. Decalogue of the Spanish Society of Arteriosclerosis to reduce therapeutic inertia;Blasco;Clin Investig Arteriosc,2017